Plain-English translation of NCT07199335 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether cabotegravir, an FDA-approved injectable medication, can effectively prevent HIV infection in people who inject drugs. The medication is given as an injection every two months over seven months. Researchers want to understand whether this treatment is safe, acceptable, and practical for this specific group of people.
People who inject drugs face a high risk of HIV infection, but traditional daily pill-based prevention hasn't always worked well for this population. This trial explores whether a longer-acting injectable option might be easier to use and more effective for people with substance use disorders.
You likely qualify if…
You likely don't qualify if…
You would come to the clinic for an initial evaluation and HIV test, then return within a week for your first injection and enrollment survey. After that, you would receive injections every one to two months for a total of five injections over seven months. At each visit, you would have brief HIV testing and answer short surveys about your experience with the medication. The study also provides support services like transportation assistance and financial incentives to help you participate.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
Massachusetts General Hospital
Collaborators
ViiV Healthcare, Fenway Community Health
Enrollment target
~100 participants
Started
February 2026
Primary completion
December 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Suzanne McCluskey, MD, MSc
Massachusetts General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.